Application No. 09/996,438
Filing Date: November 20,2001
Docket No. 5724-03-BHJ

IN THE CLAIMS

1. (amended) A pharmaceutical composition comprising:

an acid salt of a sympathomimetic amine, said sympathomimetic amine selected from the group consisting of pseudoephedrine hydrochloride, pseudoephedrine sulfate, ephedrine hydrochloride and phenylpropanolamine hydrochloride; and

at least one combination inhibitor, said combination inhibitor selected from the group consisting of an amino polymer, a salt of a transition metal and combinations thereof,

C1 wherein said amino polymer is a copolymer of methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate;

wherein said transition metal is selected from the group consisting of iron, cobalt, copper, chromium, manganese, nickel, zinc and combinations thereof.

wherein each said combination inhibitor is a single component and is present in amounts sufficient to interfere with the isolation of said sympathomimetic amine and to interfere with the conversion of said sympoathomimetic amine to other pharmacologically active compounds without significantly altering the release of said sympathomimetic amine from said pharmaceutical composition as compared to the undenatured composition.

Claims 2 – 31 previously cancelled

32
2. (previously added) The pharmaceutical composition according to claim 1 Rule 75 further comprising at least one reaction inhibitor, wherein said reaction inhibitor is

present in amounts sufficient to interfere with the conversion of said sympathomimetic amine to other pharmacologically active compounds without significantly altering the release of said sympathomimetic amine from said pharmaceutical composition as compared to the undenatured composition.

33 3. (previously added) The pharmaceutical composition according to claim 1 further comprising at least one separation inhibitor, wherein said separation inhibitor is present in amounts sufficient to interfere with the isolation of said sympathomimetic amine without significantly altering the release of said sympathomimetic amine from said pharmaceutical composition as compared to the undenatured composition.

34 4. (previously added) The pharmaceutical composition according to claim 32 2 further comprising at least one separation inhibitor, wherein said separation inhibitor is present in amounts sufficient to interfere with the isolation of said sympathomimetic amine without significantly altering the release of said sympathomimetic amine from said pharmaceutical composition as compared to the undenatured composition.

C1

35 5. (canceled)

36 6. (previously added) The pharmaceutical composition according to claim 35 5 wherein said sympathomimetic amine is pseudoephedrine hydrochloride.

37 7. (previously added) The pharmaceutical composition according to claim 1 wherein said other pharmacologically active compound is selected from the group consisting of methamphetamine, amphetamine, methacathinone and cathinone.

38 8. (previously added) The pharmaceutical composition according to claim 37 7 wherein said other pharmacologically active compound is methamphetamine.

39 ~~9~~. (canceled)

40 ~~10~~. (previously added) The pharmaceutical composition according to claim 39 ~~9~~ wherein said amino polymer is the neutralized hydrochloride salt form of the copolymer of methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate.

41 ~~11~~. (canceled)

42 ~~12~~. (previously added) The composition according to claim 1 wherein the anion of said transition metal salt is selected from the group consisting of chloride, oxide, sulfate and gluconate.

43 ~~13~~. (previously added) The composition according to claim 1 wherein said transition metal salt is selected from the group consisting of ferric chloride, ferric oxide, ferrous sulfate, ferrous chloride, ferrous gluconate, ferrous oxide, zinc gluconate, copper gluconate and combinations thereof.

C1

44 ~~14~~. (previously added) The pharmaceutical composition according to claim 43 ~~13~~ wherein said transition metal salt is selected from the group consisting of ferrous gluconate, zinc gluconate, copper gluconate and combinations thereof.

45 ~~15~~. (previously added) The pharmaceutical composition according to claims 32 ~~2~~ or 34 ~~4~~ wherein said reaction inhibitor is selected from the group consisting of water insoluble polyhydroxy compounds, non-polymeric water soluble polyhydroxy compounds, solvent soluble ester compounds and combinations thereof.

46 ~~16~~. (previously added) The pharmaceutical composition according to claim 45 ~~15~~ wherein said water insoluble polyhydroxy compound is selected from the group consisting of ethylcellulose, cellulose and combinations thereof.

47 ~~17~~. (previously added) The pharmaceutical composition according to claim ~~15~~ 45 wherein said non-polymeric water soluble polyhydroxy compound is selected from the group consisting of fructose, glycerin, sorbitol, lactitol, mannitol, xylitol, maltitol, galactose and combinations thereof.

48 ~~18~~. (previously added) The pharmaceutical composition according to claim ~~15~~ 45 wherein said solvent soluble ester is selected from the group consisting of glycerin esters, esters of glycerin polymers, sorbitol esters, propylene glycol esters, polyethylene glycol esters, sucrose esters, esters of ethoxylated fatty alcohols and combinations thereof.

C1

49 ~~19~~. (previously added) The pharmaceutical composition according to claims ~~8~~ 33 or 34 ~~4~~ wherein said separation inhibitor is selected from the group consisting of water soluble cellulose compounds, polysaccharide gums, polyethylene oxide polymers, acrylic acid polymers, starches, magnesium aluminum silicates, polyvinylpyrrolidones, clays and combinations thereof.